Welcome to our dedicated page for Viracta Therapeutics SEC filings (Ticker: VIRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viracta Therapeutics, Inc. (VIRX) SEC filings page on Stock Titan provides access to the company’s regulatory documents, including materials that reflect significant changes in its listing status and corporate trajectory. Viracta has operated as a clinical-stage precision oncology company focused on virus-associated cancers, and its filings complement the clinical and corporate information disclosed in news releases.
A key document for VIRX is the Form 25 filed with the U.S. Securities and Exchange Commission, in which Nasdaq Stock Market LLC notifies the SEC of the removal of Viracta’s common stock from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. This filing identifies Viracta Therapeutics, Inc. as the issuer and the Nasdaq Stock Market LLC as the exchange, and confirms that the company’s common stock has been struck from listing on Nasdaq.
When reviewed alongside Viracta’s public announcements—such as the February 5, 2025 release stating that the company terminated its employees and will wind down operations while exploring strategic alternatives—these filings help investors and researchers understand the regulatory and listing implications of the company’s decisions. Historical periodic reports and other submissions (where available) can provide additional detail on Viracta’s clinical programs, risk disclosures, and financial position over time.
On Stock Titan, SEC filings for VIRX are paired with AI-powered tools that summarize lengthy documents and highlight important elements, such as changes in listing status or references to strategic alternatives. Users can quickly identify the significance of forms like the Form 25, and connect these regulatory milestones to Viracta’s broader narrative in EBV-associated oncology and its subsequent wind down and delisting from the Nasdaq Stock Market.